Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of pomalidomide (CC-4047) in advanced soft tissue sarcomas
2007-005670-31Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jul 2008
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in soft tissue sarcoma (STS), sponsored by Celgene Corporation. Primary endpoint: Tumor response per RECIST. Started Jul 2008; status: terminated.
02
Drugs
pomalidomide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2007-005670-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005670-31.